Next Article in Journal
Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue
Next Article in Special Issue
Topical Administration of Cannabidiol: Influence of Vehicle-Related Aspects on Skin Permeation Process
Previous Article in Journal
Metformin Derivative HL156A Reverses Multidrug Resistance by Inhibiting HOXC6/ERK1/2 Signaling in Multidrug-Resistant Human Cancer Cells
Review

Towards Better Delivery of Cannabidiol (CBD)

1
Artelo Biosciences, 888 Prospect Street, Suite 210, La Jolla, CA 92037, USA
2
Division of Graduate Entry Medicine and Medical Sciences, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(9), 219; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090219
Received: 7 August 2020 / Revised: 26 August 2020 / Accepted: 27 August 2020 / Published: 28 August 2020
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent. View Full-Text
Keywords: cannabidiol; CBD; formulation; clinical development cannabidiol; CBD; formulation; clinical development
MDPI and ACS Style

Millar, S.A.; Maguire, R.F.; Yates, A.S.; O’Sullivan, S.E. Towards Better Delivery of Cannabidiol (CBD). Pharmaceuticals 2020, 13, 219. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090219

AMA Style

Millar SA, Maguire RF, Yates AS, O’Sullivan SE. Towards Better Delivery of Cannabidiol (CBD). Pharmaceuticals. 2020; 13(9):219. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090219

Chicago/Turabian Style

Millar, Sophie A., Ryan F. Maguire, Andrew S. Yates, and Saoirse E. O’Sullivan 2020. "Towards Better Delivery of Cannabidiol (CBD)" Pharmaceuticals 13, no. 9: 219. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090219

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop